TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06846606: Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 69 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT06846606 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06846606 Rescue Dossier →